Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million, according to a Wednesday filing with the Australian bourse.

The company is entitled to one-third of the proceeds of the sale under its license agreement with Acadia, according to the filing.

The PRV was granted by the US Food and Drug Administration after the approval of Daybue for Rett syndrome treatment, the filing said.

Neuren Pharmaceuticals shares rose past 6% in midday trade Wednesday.

Price (AUD): $13.04, Change: $+0.77, Percent Change: +6.28%